tbuckley/cabot-search huggingface dataset:
3d Telomere Signatures of Hodgkin-Cells at Diagnosis Identify Patients with Poor Response to Conventional Chemotherapy
Authors: H. Knecht, N. Kongruttanachok, B. Sawan, J. Brossard, S. Prévost, É. Turcotte, Z. Lichtensztejn, D. Lichtensztejn, S. Mai
Journal: Annals of Oncology (2012)
Immunotherapy in sepsis - brake or accelerate?
Authors: Folkert Steinhagen, Susanne V. Schmidt, Jens-Christian Schewe, Konrad Peukert, Dennis M. Klinman, Christian Bode
Journal: Pharmacology & Therapeutics (2020)

Sepsis, a life threating syndrome characterized by organ failure after infection, is the most common cause of death in hospitalized patients. The treatment of sepsis is generally supportive in nature, involving the administration of intravenous fluids, vasoactive substances and oxygen plus antibiotics to eliminate the pathogen. No drugs have been approved specifically for the treatment of sepsis, and clinical trials of potential therapies have failed to reduce mortality - suggesting that new approaches are needed. Abnormalities in the immune response elicited by the pathogen, ranging from excessive inflammation to immunosuppression, contribute to disease pathogenesis. Although hundreds of immunomodulatory agents are potentially available, it remains unclear which patient benefits from which immune therapy at a given time point. Results indicate the importance of personalized therapy, specifically the need to identify the type of intervention required by each individual patient at a given point in the disease process. To address this issue will require using biomarkers to stratify patients based on their individual immune status. This article reviews recent and ongoing clinical investigations using immunostimulatory or immunosuppressive therapies against sepsis including non-pharmacological and novel preclinical approaches.
RNA isoform screens uncover the essentiality and tumor-suppressor activity of ultraconserved poison exons
Authors: James D. Thomas, Jacob T. Polaski, Qing Feng, Emma J. De Neef, Emma R. Hoppe, Maria V. McSharry, Joseph Pangallo, Austin M. Gabel, Andrea E. Belleville, Jacqueline Watson, Naomi T. Nkinsi, Alice H. Berger, Robert K. Bradley
Journal: Nature Genetics (2020)
Phase II Trial of TS-1 in Combination with Oxaliplatin (SOX) in Patients with Metastatic Breast Cancer (MBC) Previously Treated with Anthracycline and Taxane Chemotherapy [TORCH] [Korean Cancer Study Group (KCSG) BR07-03]
Authors: S.-A. Im, K.H. Lee, D.-Y. Oh, K.S. Lee, J.-H. Ahn, J. Sohn, J.S. Ahn, J.H. Kim, M.H. Lee, K.E. Lee, S.-Y. Kim, S.B. Kim, Y.-H. Im, J. Ro, H.-S. Park
Journal: Annals of Oncology (2012)
OP0305 Type I IFN system activation in newborns exposed to ANTI-RO/SSA autoantibodies in utero
Authors: M Wahren, M Hedlund, GE Thorlacius, M Ivanchenko, N Kyriakidis, L Rönnblom, M-L Eloranta, A Espinosa, S-E Sonesson
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Overexpression of type I IFN-stimulated genes has been demonstrated in both SLE and SS, and induction of IFNα production in plasmacytoid dendritic cells by immune complexes containing RNA and autoantibodies, including Ro/SSA and La/SSB autoantibodies, has also been shown. During pregnancy, these autoantibodies pass over the placenta to the fetus, but it is not know if an IFN-activation takes place also in the fetus. <h3>Objectives</h3> In the present study, we investigated if the type I IFN system is activated in newborns exposed to anti-Ro/SSA autoantibodies <i>in utero</i>. <h3>Methods</h3> Anti-Ro/SSA positive mothers and their babies as well as healthy controls were included in the study. Maternal and cord blood drawn at birth was immediately separated into plasma and PBMC. mRNA expression was analyzed by microarrays, cell surface markers were assessed by flow cytometry and circulating IFNα levels by DELFIA. <h3>Results</h3> We observed increased expression of IFN-regulated genes and elevated plasma IFNα levels not only in anti-Ro/SSA positive women but also in their newborns, with maternal and fetal IFN scores showing a significant positive correlation (r=0.74, p=0.005). Increased expression of MHC class II was observed on CD14<sup>+</sup> monocytes of anti-Ro/SSA antibody-exposed babies, suggesting cellular activation. Notably, the IFN score of babies born to mothers receiving immunomodulatory treatment was similar to that of controls. <h3>Conclusions</h3> We demonstrate for the first time that anti-Ro/SSA antibody-exposed babies at risk for neonatal lupus have a pre-activated immune system with an IFN signature, elevated plasma IFNα, and increased MHC class II expression on circulating monocytes. Our data also suggest that maternal immunomodulatory treatment may modulate the IFN activity in the baby. <h3>Disclosure of Interest</h3> None declared
心房細動/粗動及び左室機能障害を有する患者における心拍数増加の緊急管理-超短時間作用型β1選択的ブロッカーであるランジオロールとジゴキシンの比較(J-Land試験)-
Authors: Nagai Ryozo, Kinugawa Koichiro, Inoue Hiroshi, Atarashi Hirotsugu, Seino Yoshihiko, Yamashita Takeshi, Shimizu Wataru, Aiba Takeshi, Kitakaze Masafumi, Sakamoto Atsuhiro, Ikeda Takanori, Imai Yasushi, Daimon Takashi, Fujino Katsuhiro, Nagano Tetsuji, Okamura Tatsuaki, Hori Masatsugu
Journal: Circulation (2013)
P2.26 Effect of Thymoquinon on 1,2-Dimethyl-Hydrazine-Induced Oxidative Stress During Initiation and Promotion of Colon Carcinogenesis in Rats
Authors: J.H. Hanen, B.H.K. Sonia, M. Aya, H. Zohra, M. Touhami
Journal: Annals of Oncology (2012)
薬物溶出ステント留置術後のステント内ネオアテローム性動脈硬化症のin vivo評価-光干渉断層法研究
Authors: Miwa Kenji, Matsubara Takao, Yasuda Toshihiko, Inoue Masaru, Ukawa Nobuo, Okada Hirofumi, Yakuta Yohei, Matsui Takao, Kawashiri Masaaki, Yamagishi Masakazu, Kanaya Honin
Journal: Circulation (2013)
Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
Authors: R. Chugh, K.A. Griffith, E.J. Davis, D.G. Thomas, J.D. Zavala, G. Metko, B. Brockstein, S.D. Undevia, W.M. Stadler, S.M. Schuetze
Journal: Annals of Oncology (2019)
Hypoxia and Metabolism Gene Expression Profile Predicts Poor Survival in Head and Neck Carcinoma
Authors: S. Gouerant, S. Mareschal, J.M. Picquenot, A. Berghian, M. Cornic, O. Choussy, M. Benard, F. Di Fiore, F. Jardin, F. Clatot
Journal: Annals of Oncology (2012)
P-0245 Vegf Serum Level after Chemoembolization With Drug-Eluting Beads (Debiri) in Patients With Liver Metastases of Chemotherapy Refractory Colorectal Cancer
Authors: Stefan Pluntke, Sven Dyrda, Hansjochen Wilke, Stahl Michael, Rolf Dappen, Jens-Albrecht Koch
Journal: Annals of Oncology (2012)
MLN8237 (ALISERTIB), An Investigational Aurora a Kinase Inhibitor, in Patients (PTS) with Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Breast Cancer (BRC), Head and Neck Squamous Cell Carcinoma (HNSCC), And Gastroesophageal Cancer (GE): Emerging Phase (PH) 2 Results
Authors: B. Melichar, P. Lee, R.H. Alvarez, M. Degardin, J. Bennouna, C. Schusterbauer, B. Zhang, E. Benaim, P. Rosen
Journal: Annals of Oncology (2012)
Biomarker (BM) Results from GOG-0218, a Phase 3 Trial of Front-Line Bevacizumab (BV) + Chemotherapy (CT) for Ovarian Cancer (OC)
Authors: M.J. Birrer, H. Lankes, R.A. Burger, R. Mannel, H. Homesley, V. Henschel, M. Sovak, S.J. Scherer, S. de Haas, C. Pallaud
Journal: Annals of Oncology (2012)
Achieving Health Equity in Preventive Services: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop
Authors: Heidi D. Nelson, Amy Cantor, Jesse Wagner, Rebecca Jungbauer, Ana Quiñones, Lucy Stillman, Karli Kondo
Journal: Annals of Internal Medicine (2020)

Disadvantaged populations in the United States experience disparities in the use of preventive health services.To examine effects of barriers that create health disparities in 10 recommended preventive services for adults, and to evaluate the effectiveness of interventions to reduce them.English-language searches of Ovid MEDLINE, PsycINFO, SocINDEX, and the Veterans Affairs Health Services database (1 January 1996 to 5 July 2019); reference lists.Trials, observational studies with comparison groups, and systematic reviews of populations adversely affected by disparities that reported effects of barriers on use of any of the 10 selected preventive services or that reported the effectiveness of interventions to reduce disparities in use of a preventive service by improving intermediate or clinical outcomes.Dual extraction and assessment of study quality, strength of evidence, and evidence applicability.No studies reported effects of provider-specific barriers on preventive service use. Eighteen studies reporting effects of patient barriers, such as insurance coverage or lack of a regular provider, on preventive service use had mixed and inconclusive findings. Studies of patient-provider interventions (n = 12), health information technologies (n = 11), and health system interventions (n = 88) indicated higher cancer screening rates with patient navigation; telephone calls, prompts, and other outreach methods; reminders involving lay health workers; patient education; risk assessment, counseling, and decision aids; screening checklists; community engagement; and provider training. Single studies showed that clinician-delivered and technology-assisted interventions improved rates of smoking cessation and weight loss, respectively.Insufficient or low strength of evidence and applicability for most interventions except patient navigation, telephone calls and prompts, and reminders involving lay health workers.In populations adversely affected by disparities, patient navigation, telephone calls and prompts, and reminders involving lay health workers increase cancer screening.National Institutes of Health Office of Disease Prevention through an interagency agreement with the Agency for Healthcare Research and Quality. (PROSPERO: CRD42018109263).
First-Line Dacomitinib (PF-00299804), an Irreversible Pan-Her Tyrosine Kinase Inhibitor, for Patients with EGFR-Mutant Lung Cancers
Authors: M.G. Kris, T. Mok, S.-H.I. Ou, R.G. Martins, D.-W. Kim, Z. Goldberg, H. Zhang, I. Taylor, S.P. Letrent, P.A. Jänne
Journal: Annals of Oncology (2012)
P-0298 18F-Faza Pet/Ct in Patients with Rectal Cancer
Authors: Birgitte Havelund, Paw Holdgaard, Søren Rafaelsen, John Ploen, Lise Mortensen, Joern Theil, Dirk Bender, Karen-Lise Spindler, Anders Jakobsen
Journal: Annals of Oncology (2012)
Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents
Authors: Christine Ferrara-Cook, Susan Michelle Geyer, Carmella Evans-Molina, Ingrid M. Libman, Dorothy J. Becker, Stephen E. Gitelman, Maria Jose Redondo
Journal: Diabetes Care (2020)

Sustained excess BMI increases the risk of type 1 diabetes (T1D) in autoantibody-positive relatives without diabetes of patients. We tested whether elevated BMI also accelerates the progression of islet autoimmunity before T1D diagnosis.We studied 706 single autoantibody-positive pediatric TrialNet participants (ages 1.6-18.6 years at baseline). Cumulative excess BMI (ceBMI) was calculated for each participant based on longitudinally accumulated BMI ≥85th age- and sex-adjusted percentile. Recursive partitioning analysis and multivariable modeling defined the age cut point differentiating the risk for progression to multiple positive autoantibodies.At baseline, 175 children (25%) had a BMI ≥85th percentile. ceBMI range was -9.2 to 15.6 kg/m2 (median -1.91), with ceBMI ≥0 kg/m2 corresponding to persistently elevated BMI ≥85th percentile. Younger age increased the progression to multiple autoantibodies, with age cutoff of 9 years defined by recursive partitioning analysis. Although ceBMI was not significantly associated with progression from single to multiple autoantibodies overall, there was an interaction with ceBMI ≥0 kg/m2, age, and HLA (P = 0.009). Among children ≥9 years old without HLA DR3-DQ2 and DR4-DQ8, ceBMI ≥0 kg/m2 increased the rate of progression from single to multiple positive autoantibodies (hazard ratio 7.32, P = 0.004) and conferred a risk similar to that in those with T1D-associated HLA haplotypes. In participants <9 years old, the effect of ceBMI on progression to multiple autoantibodies was not significant regardless of HLA type.These data support that elevated BMI may exacerbate islet autoimmunity prior to clinical T1D, particularly in children with lower risk based on age and HLA. Interventions to maintain normal BMI may prevent or delay the progression of islet autoimmunity.
Jellyfish Sting—In Vivo Imaging for Diagnosis and Treatment Monitoring
Authors: Alessandro Di Stefani, Simone Cappilli, Ketty Peris
Journal: JAMA Dermatology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Prediagnostic Immune Cell Profiles and Breast Cancer
Authors: Jacob K. Kresovich, Katie M. O’Brien, Zongli Xu, Clarice R. Weinberg, Dale P. Sandler, Jack A. Taylor
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Higher overall leukocyte counts in women may be associated with increased risk of breast cancer, but the association of specific leukocyte subtypes with breast cancer risk remains unknown. <h3>Objective</h3> To determine associations between circulating leukocyte subtypes and risk of breast cancer. <h3>Design, Setting, and Participants</h3> Between 2003 and 2009, the Sister Study enrolled 50 884 women who had a sister previously diagnosed with breast cancer but were themselves breast cancer free. A case-cohort subsample was selected in July 2014 from the full Sister Study cohort. Blood samples were obtained at baseline, and women were followed up through October 2016. Data analysis was performed in April 2019. <h3>Main Outcomes and Measures</h3> The main outcome was the development of breast cancer in women. Whole-blood DNA methylation was measured, and methylation values were deconvoluted using the Houseman method to estimate proportions of 6 leukocyte subtypes (B cells, natural killer cells, CD8<sup>+</sup>and CD4<sup>+</sup>T cells, monocytes, and granulocytes). Leukocyte subtype proportions were dichotomized at their population median value, and Cox proportional hazard models were used to estimate associations with breast cancer. <h3>Results</h3> Among 2774 non-Hispanic white women included in the analysis (mean [SD] age at enrollment, 56.6 [8.8] years), 1295 women were randomly selected from the full cohort (of whom 91 developed breast cancer) along with an additional 1479 women who developed breast cancer during follow-up (mean [SD] time to diagnosis, 3.9 [2.2] years). Circulating proportions of B cells were positively associated with later breast cancer (hazard ratio [HR], 1.17; 95% CI, 1.01-1.36;<i>P</i> = .04). Among women who were premenopausal at blood collection, the association between B cells and breast cancer was significant (HR, 1.38; 95% CI, 1.05-1.82;<i>P</i> = .02), and an inverse association for circulating proportions of monocytes was found (HR, 0.75; 95% CI, 0.57-0.99;<i>P</i> = .05). Among all women, associations between leukocyte subtypes and breast cancer were time dependent: higher monocyte proportions were associated with decreased near-term risk (within 1 year of blood collection, HR, 0.62; 95% CI, 0.43-0.89;<i>P</i> = .01), whereas higher B cell proportions were associated with increased risk 4 or more years after blood collection (HR, 1.38; 95% CI, 1.15-1.67;<i>P</i> = .001). <h3>Conclusions and Relevance</h3> Circulating leukocyte profiles may be altered before clinical diagnoses of breast cancer and may be time-dependent markers for breast cancer risk, particularly among premenopausal women.
Gastrointestinal Stromal Tumors of the Stomach with Kit Exon 9 Mutations Mostly Present with a Favorable Prognosis
Authors: E. Wardelmann, H. Löser, W. Jeske, S. Merkelbach-Bruse, P. Hohenberger, P. Reichardt, S. Bauer, R. Buettner, S. Huss, H. Schildhaus
Journal: Annals of Oncology (2012)
Pitfalls of Using the Cockcroft-Gault Formula When Calculating Carboplatin Dose for the Adjuvant Treatment of Patients with Stage i Seminoma
Authors: M. Fehr, T. Geldart, H. Sun, P.D. Simmonds, G. Mead, M. Wheater, N. Nagaraj, S. Ellis, R. von Moos, R. Cathomas
Journal: Annals of Oncology (2012)
P-0144 Adjuvant Therapy and Prognostic Factors for Biliary Tract Cancer Intrahepatic Cholangiocarcinoma: Single-Center Experience
Authors: Joaquina Martinez-Galan, Javier Garcia Garcia, Karim Muffa K-Granero, José Antonio Ortega, Beatriz Gonzalez-Astorga, Verónica Conde, Daniel Garrote, Aranzazú González-Vicente, Jose Antonio Ferrón, Juan Ramón Delgado
Journal: Annals of Oncology (2012)
Kras Mutational Status and Oxaliplatin Sensitivity: The Other Side of the Moon?
Authors: A. Orlandi, M. Di Salvatore, M. Basso, C. Bagalà, A. Strippoli, A. Calegari, A. Astone, C. Pozzo, A. Cassano, C. Barone
Journal: Annals of Oncology (2012)
The Neutropenia Prophylaxis Evaluation Program in Patients Receiving Myelosuppressive Chemotherapy with Moderate or High Risk of Febrile Netropenia – an Interim Analysis of the Diepp Study
Authors: T. Csoszi, M. Safanda, G. Mazur, G. Mihaylov, J. Benkoviová, E. Tóth
Journal: Annals of Oncology (2012)
Dose-Escalation Phase I Study of Cabazitaxel (CBZ) + Gemcitabine (GEM) in Patients (PTS) with Metastatic or Unresectable Advanced Solid Malignancy
Authors: O. Rixe, I. Puzanov, P.M. LoRusso, J. Yin, S. Doroumian, X. Zhi, A.J. Olszanski
Journal: Annals of Oncology (2012)
Beta 4 Integrin Polymorphism Mediate an Alternative Resistance Pathway in HER-3 Negative, K-RAS Wild Type Metastatic Colorectal Patients Receiving Irinotecan Cetuximab
Authors: M. Scartozzi, R. Giampieri, C. Loretelli, A. Mandolesi, L. Faloppi, M. Bianconi, S. Biagetti, S. Alfonsi, I. Bearzi, S. Cascinu
Journal: Annals of Oncology (2012)
Two decades of therapy in metastatic colorectal cancer (mCRC): An analysis to discern the contribution and progress made by chemotherapy.
Authors: Irfan Jawed, Julia Wilkerson, Austin G. Duffy, Antonio Tito Fojo
Journal: Journal of Clinical Oncology (2012)

e14064 Background: The past 20 years have seen progress in mCRC with more effective agents and better medical, surgical and supportive care. Methods: Systematic review of 101 phase III and large phase II trials in mCRC to quantify benefit over time with first-line and subsequent therapies. Outcomes in the experimental (EA) and control arms (CA) included progression-free survival (PFS), overall response rate (ORR), stable disease (SD), and overall survival (OS). Data were analyzed according to dates of publication and median enrollment. Results: Significant outcomes are reported; most had R 2 values &gt; 0.6. OS of EA improved 0.83 mos/yr. Importantly OS of CA improved 0.58 mos/yr likely reflecting subsequent use of experimental regimens in CA and improvement in mCRC care over time. Chemotherapy has contributed only partly to gains in OS since (1) only modest improvements of PFS (0.33 [EA] and 0.26 [CA] mos/yr) and we have shown OS gains are proportional to PFS gains indicating other factors are as or more important than chemotherapy; and (2) lack of OS improvement in 14 second/subsequent line trials. Furthermore, to assess the contribution of each drug/drug class to improvement in OS we performed linear regression with OS the dependent variable versus time publication. We found oxaliplatin, irinotecan and bevacizumab have contributed to progress; but not cetuximab/panitumumab likely explained by inclusion of pts with tumors harboring mutant ras in studies. Not surprisingly, capecitabine in place of 5-fluorouracil had no impact on progress made. As expected PFS correlates highly with OS, but importantly ORR had very high correlations with both PFS and OS. SD was an “adverse” outcome, OS decreasing as SD rates increase. Conclusions: OS of mCRC patients has improved gradually over the past two decades, with gains from chemotherapy and importantly gains from other factors, including lead-time bias, better loco-regional approaches and supportive care. Gains from first line therapies have been modest but consistent; gains from second line therapies have been disappointing. We believe future progress will be more fruitful if emphasis is given to improving second line therapies.
Proliferation Determined by KI67 Marker Defines Pathological Complete Response in a Dose-Dense Neoadjuvant Chemotherapy Schedule in Locally Advanced Breast Cancer Patients
Authors: M.Y. Plata Fernandez, A. Sanchez-Muñoz, A. Jaén-Morago, M. Lomas-Garrido, M. Fernández, C. Llacer, M. Fernández, N. Ribelles, E. Alba-Conejo, P. Sánchez-Rovira
Journal: Annals of Oncology (2012)
Early Lymph Node Metastasis: Altered Microrna Expression in Colon Cancer
Authors: M. Rammer, H. Rumpold, H. Bösmüller, R. Marschon, T. Malli, W. Kranewitter, M. Erdel, S. Deutschbauer, A.L. Petzer, G. Webersinke
Journal: Annals of Oncology (2012)
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study of Onartuzumab (METMAB) in Combination with Paclitaxel + Cisplatin (or Carboplatin) as First-Line Treatment for Patients (PTS) With Stage IIIB or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Authors: F.R. Hirsch, D. Gandara, R. Govindan, V.E. Paton, W. Yu
Journal: Annals of Oncology (2012)
HDAC inhibition improves cardiopulmonary function in a feline model of diastolic dysfunction
Authors: Markus Wallner, Deborah M. Eaton, Remus M. Berretta, Laura Liesinger, Matthias Schittmayer, Juergen Gindlhuber, Jichuan Wu, Mark Y. Jeong, Ying H. Lin, Giulia Borghetti, Sandy T. Baker, Huaqing Zhao, Jessica Pfleger, Sandra Blass, Peter P. Rainer, Dirk von Lewinski, Heiko Bugger, Sadia Mohsin, Wolfgang F. Graier, Andreas Zirlik, Timothy A. McKinsey, Ruth Birner-Gruenberger, Marla R. Wolfson, Steven R. Houser
Journal: Science Translational Medicine (2020)

Histone deacetylase inhibition counteracts adverse left ventricular remodeling, improves pulmonary function, and reverses diastolic dysfunction.
Rituximab Induced Internalisation of B-Cells CD20 Receptor is Independent of the Inhibitory FC Receptor (CD32B) Intracellular Cell Signalling
Authors: V. Shah, A. McIntosh, C.H.T. Chan, S.H. Lim, A.T. Vaughan, M.J. Glennie, A. Roghanian, M.S. Cragg
Journal: Annals of Oncology (2012)